Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Renalytix plc (RNLX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
10/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
10/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
10/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
10/02/2023 RW WD Form RW WD - Withdrawal of Registration Withdrawal Request:
10/02/2023 RW Form RW - Registration Withdrawal Request:
09/28/2023 8-K Quarterly results
09/28/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
09/28/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
09/28/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
09/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
09/28/2023 10-K Annual Report for the period ended June 30, 2023
08/21/2023 8-K Regulation FD Disclosure  Interactive Data
07/17/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Renalytix plc Issue of Shares LONDON and SALT LAKE CITY – July 17, 2023 - Renalytix plc , announces the repayment of $1.06 million of the Company’s convertible bond, further details of which were announced on 31 March 2022. The repayment is being made through the issue of 526,211 American Depositary Shares . After settlement of the repayment, the principal remaining under the convertible bond will be reduced by $1.06 million to $15.90 million. 1,052,422 new ordinary shares of £0.0025 each in the capital of the Company will be issued to settle the conversion of 526,211 ADSs, with each ADS representing two Ordinary Shares. An application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 1,052,422 new ..."
07/03/2023 8-K Appointed a new director
Docs: "Renalytix plc Directorate Change Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors LONDON and SALT LAKE CITY – July 3, 2023 - Renalytix plc , the first company to commercialize an FDA approved artificial intelligence enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the appointment of Catherine Coste to the Company’s Board of Directors, effective June 30, 2023. Ms. Coste was also appointed as the Non-Executive Chair of the Audit Committee and a member of the Renumeration Committee. Ms. Coste has extensive financial experience having retired from Deloitte and Touche LLP in 2020, where she was a senior partner and served as one of Deloitte’s life sciences industry executive leaders. She spent 32 years in bo..."
07/03/2023 8-K Regulation FD Disclosure  Interactive Data
06/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"About Chronic Kidney Disease Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention estimates that 15% of US adults, more than 38 million people, currently have chronic kidney disease . Diabetes is the leading cause of kidney failure, accounting for 44% of new cases. Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.1 Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year, kidney disease kills more people than breast and prostate cancer. Every day, 13 patients i..."
06/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
06/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
05/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"General Meeting attendance The general meeting will be held on 8 June 2023 at 3:00 p.m. . The General Meeting will be held at 6 Stratton Street Mayfair, London W1J 8LD. This letter does not contain the full details of the resolutions to be tabled at the General Meeting but these are contained in the Notice of General Meeting and should be read before you complete your vote. The Directors consider that the proposed resolutions contained in the Notice of General Meeting are in the best interests of the Company and shareholders as a whole and unanimously recommend that you vote in favour of them, as they intend to do in respect of their own shareholdings. Proxy voting You will not receive a hard copy form of proxy for the General Meeting in the post. Instead, you will be able to vote electron...",
"RENALYTIX PLC Notice of General Meeting No person should construe the contents of this document as legal, tax or financial advice and recipients of this document should consult their own advisers as to the matters described in this document. This document should be read as a whole. Your attention is drawn to the letter from Christopher Mills, the Non-Executive Chairman of the Company, on pages 5 to 7 of this document in which the Directors recommend that you vote in favour of each of the Resolutions to be proposed at the General Meeting referred to below. Cautionary note regarding forward-looking statements: This document contains statements about the Company that are or may be “forward-looking statements”. All statements, other than statements of historical facts, included i..."
05/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Renalytix plc Notice of General Meeting and Posting of Circular LONDON and SALT LAKE CITY, May 11, 2023 - Renalytix announces that a circular containing a notice convening a General Meeting to be held at the offices of Harwood Capital LLP, 6 Stratton Street Mayfair, London W1J 8LD at 3 p.m. on 8 June 2023, has today been posted to the Company’s shareholders. An electronic copy of the circular will shortly be available on the Company’s website at www.renalytix.com in accordance with AIM Rule 20. For further information, please contact: Renalytix plc www.renalytix.com James McCullough, CEO Via Walbrook PR Stifel Tel: 020 7710 7600 Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea Investec Bank plc Tel: 020 7597 4000 Gary Clarence / Shalin Bhamra Walbrook PR Limited Tel: 020 7933..."
05/11/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/02/2023 F-3 Form F-3 - Registration statement by foreign private issuers:
03/30/2023 6-K Quarterly results
03/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
03/21/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
03/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
02/14/2023 SC 13G/A GILDER GAGNON HOWE & CO LLC reports a 2.7% stake in Renalytix plc
02/10/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
02/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Renalytix plc Renalytix announces a c.$20.3 million private placement LONDON and SALT LAKE CITY, February 8, 2023 -- Renalytix plc announces a c.$20.3 million private placement of Ordinary Shares and American Depositary Shares .",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of February 7, 2023 , by and among Renalytix plc, a public limited company incorporated under the laws of England and Wales , and each purchaser identified on the signature pages hereto . Whereas, the Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Regulation S promulgated under the Securities Act of 1933, as amended , solely to prospective investors in the United Kingdom. Whereas, each Purchaser wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, ordinary shares, nominal value £0.0025 per share , in the numbers set forth opposite such Purchaser’s name on hereto . T...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of February 7, 2023 , by and among Renalytix plc, a public limited company incorporated under the laws of England and Wales , and each purchaser identified on the signature pages hereto . Whereas, the Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act of 1933, as amended , solely to prospective investors in the United States. Whereas, each Purchaser wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, American Depositary Shares , each representing two ordinary shares, nominal value £0.0025 per share , in the numbers set forth opposite suc...",
"REGISTRATION RIGHTS AGREEMENT by and between The Hamilton E. James 2003 Childrens Trust and Renalytix plc ___________________________________ Dated as of February 6, 2023 Table of Contents Page 1. Certain Definitions. 1 2. Shelf Registration Statement. 3 3. Piggyback Registrations. 4 4. Other Registrations 5 5. Selection of Underwriters. 5 6. Procedures. 5 7. Registration Expenses. 9 8. Board Appointment. 10 9. Indemnification. 12 10. Term of Agreement. 13 11. Transfer of Registration Rights. 14 12. Conversion or Exchange of Other Securities. 14 13. Miscellaneous. 14 i Registration Rights Agreement dated as of February 6, 2023, by and between Renalytix plc, incorporated and registered in England and Wales with company number 11257655 , and The Hamilton E. James 2003 Childrens Trust , and f..."
12/20/2022 6-K Quarterly results
11/30/2022 6-K Quarterly results
11/29/2022 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy